Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease.
Boulanger
E
E
Meignin
V
V
Leverger
G
G
Solal-Céligny
P
P
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D012074:Remission Induction; D000069283:Rituximab; D013154:Spleen / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D000970:Antineoplastic Agents; D000069283:Rituximab